Assessing Bio-Rad (BIO) Valuation After Recent Share Price Weakness And Longer-Term Return Pressures

Recent trading in Bio-Rad Laboratories (BIO) has drawn attention after a series of negative returns over the past month and past 3 months, prompting investors to reassess what the current share price may already reflect.

See our latest analysis for Bio-Rad Laboratories.

With the share price at US$256.56 after a 12.26% one-day and 18.17% 30-day share price decline, recent weakness sits against a longer backdrop of pressured total shareholder returns, including a 46.91% 3-year and 59.72% 5-year total shareholder return decline. This suggests sentiment has been cautious and risk perceptions have shifted.

If this move in Bio-Rad has you looking across the sector, it could be a good moment to scan other life sciences and healthcare technology names using our screener for 25 healthcare AI stocks.

With the shares having fallen sharply and trading at a discount to some estimated value measures, the key question is whether Bio-Rad is now undervalued or whether the market is already pricing in its future growth outlook.

Most Popular Narrative: 26.3% Undervalued

At a last close of $256.56 versus a narrative fair value of $348, the current price sits well below what the most followed model implies.

Resilience and stable growth in consumables and reagents, demonstrated by high single-digit growth, especially in the face of delayed academic and instrument funding, are shifting Bio-Rad's sales mix toward higher-margin, recurring revenues, supporting overall profitability and cash flow stability.

Read the complete narrative.

Curious how a company with cautious earnings forecasts still lands at a higher fair value? Revenue mix, margin assumptions and a punchy future earnings multiple sit at the heart of this narrative, along with expectations for shrinking share count and a specific discount rate that pulls everything back to today.

Result: Fair Value of $348 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to weigh soft instrument demand and margin pressure from underused manufacturing capacity, along with policy and reimbursement risks in key diagnostics markets.

Find out about the key risks to this Bio-Rad Laboratories narrative.

Build Your Own Bio-Rad Laboratories Narrative

If you see the numbers differently or prefer to test your own assumptions against the data, you can build a custom view in minutes with Do it your way.

A great starting point for your Bio-Rad Laboratories research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you stop at just one stock, you could miss out on other opportunities that better fit your goals, risk comfort and income needs right now.

• Target potential mispricings by scanning our list of 53 high quality undervalued stocks that pair solid fundamentals with prices the market may not fully appreciate.
• Strengthen your income stream by reviewing 12 dividend fortresses that focus on higher-yield payers with an emphasis on durability.
• Sleep a little easier by checking 84 resilient stocks with low risk scores built around companies with lower risk scores and more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com